We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Hologic (HOLX - Free Report) closed at $72 in the latest trading session, marking a +0.26% move from the prior day. This move outpaced the S&P 500's daily gain of 0.07%. At the same time, the Dow added 0.02%, and the tech-heavy Nasdaq gained 0.01%.
Heading into today, shares of the medical device maker had lost 1.83% over the past month, lagging the Medical sector's loss of 1.58% and the S&P 500's gain of 0.38% in that time.
Hologic will be looking to display strength as it nears its next earnings release. In that report, analysts expect Hologic to post earnings of $0.85 per share. This would mark year-over-year growth of 3.66%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $941.83 million, down 1.2% from the year-ago period.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.92 per share and revenue of $4.03 billion. These results would represent year-over-year changes of -34.88% and -17.19%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Hologic currently has a Forward P/E ratio of 18.31. This represents a discount compared to its industry's average Forward P/E of 27.29.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
Hologic (HOLX - Free Report) closed at $72 in the latest trading session, marking a +0.26% move from the prior day. This move outpaced the S&P 500's daily gain of 0.07%. At the same time, the Dow added 0.02%, and the tech-heavy Nasdaq gained 0.01%.
Heading into today, shares of the medical device maker had lost 1.83% over the past month, lagging the Medical sector's loss of 1.58% and the S&P 500's gain of 0.38% in that time.
Hologic will be looking to display strength as it nears its next earnings release. In that report, analysts expect Hologic to post earnings of $0.85 per share. This would mark year-over-year growth of 3.66%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $941.83 million, down 1.2% from the year-ago period.
HOLX's full-year Zacks Consensus Estimates are calling for earnings of $3.92 per share and revenue of $4.03 billion. These results would represent year-over-year changes of -34.88% and -17.19%, respectively.
Investors should also note any recent changes to analyst estimates for Hologic. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hologic is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, Hologic currently has a Forward P/E ratio of 18.31. This represents a discount compared to its industry's average Forward P/E of 27.29.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 111, putting it in the top 45% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.